Published in Stat Methods Med Res on February 19, 2008
Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst (2009) 4.17
The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol (2011) 1.33
In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist (2011) 1.09
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open (2013) 1.07
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol (2009) 1.02
Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica (2011) 0.96
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res (2012) 0.89
Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer (2013) 0.77
Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. J Natl Cancer Inst (2016) 0.75
Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res (2007) 2.47
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res (2006) 2.07
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist (2005) 1.81
FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist (2005) 1.66
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res (2005) 1.36
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res (2012) 1.31
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 1.31
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res (2003) 1.29
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res (2013) 1.27
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist (2010) 1.25
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist (2010) 1.24
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist (2005) 1.12
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) (2007) 1.11
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 1.10
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res (2008) 1.08
Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res (2005) 1.04
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res (2008) 1.00
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res (2006) 0.99
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park) (2007) 0.95
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Oncologist (2008) 0.93
Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2010) 0.93
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res (2013) 0.93
Accelerated approval and oncology drug development timelines. J Clin Oncol (2010) 0.90
Overestimation of the effect size in group sequential trials. Clin Cancer Res (2012) 0.90
US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol (2012) 0.89
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist (2012) 0.87
An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials (2013) 0.86
Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial. Clin Cancer Res (2012) 0.86
Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. J Natl Cancer Inst Monogr (2007) 0.85
Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials. Clin Cancer Res (2013) 0.82
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) (2006) 0.82
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res (2005) 0.79
Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia. Blood (2010) 0.76
Q&A: Rajeshwari Sridhara, Robert Temple on trial design. Interviewed by Suzanne Rose. Cancer Discov (2013) 0.75